Ikeda Mohando, Celebrating 100 Years of 'Muhi', Adopts 'STiV' Generative AI Knowledge Management System

FanLead, an ICT subsidiary of Taiyo Holdings, announced that its proprietary generative AI-based knowledge management system, 'STiV,' has been fully implemented in the Quality Assurance Department of Ikeda Mohando, known for the 'Muhi' series of OTC drugs.

This implementation has successfully reduced Ikeda Mohando's operational time by 50% by leveraging OCR functionality to digitize handwritten documents.

As Ikeda Mohando approaches the 100th anniversary of its anti-itch medication 'Muhi' in 2026, the company faced challenges regarding the searchability of vast, accumulated paper records, information scattered across multiple systems, and the reliance on veteran employees' personal expertise. Rapid access to historical quality event data and regulatory information is essential for quality assurance, making digitization and centralized management an urgent priority.

Key results of the STiV implementation: 1. Drastic reduction in information search time: Centralizing scattered historical quality event data and regulatory information has streamlined investigative tasks. 2. Efficiency gains via OCR: Handwritten documents from factory sites are instantly converted to text. The time required for reading handwritten notes and drafting reports has been reduced by half (from approximately one hour to 30 minutes). 3. Advanced cause analysis using generative AI: AI is being used experimentally to draft preliminary 'Five Whys' analyses based on deviation reports.

The Quality Assurance Group at Ikeda Mohando commented that they can now centrally utilize information in environments where paper and electronic data coexist. FanLead will continue to support deeper integration with Ikeda Mohando's existing systems and continue updating STiV as an AI solution contributing to improved quality and reliability in the pharmaceutical industry.